# Corbus Pharmaceuticals

Source: https://onco.cc/companies/corbus-pharmaceuticals/  
OnCo record `corbus-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Corbus Pharmaceuticals is a United States-based biotechnology company running 2 late-stage cancer trials of CRB-601 monoclonal antibody and CRB-701.

## Summary

Corbus Pharmaceuticals, based in Norwood, MA, the United States, is a biotechnology company. Corbus Pharmaceuticals is a pharmaceutical company developing cancer treatments, including a Nectin-4-targeted therapy, alongside an obesity programme. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing CRB-601 monoclonal antibody and CRB-701. The largest, NCT06265727 (A Phase 1/2 Study to Investigate CRB-701 in Solid Tumours), plans to enrol 348 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Corbus Pharmaceuticals Inc.
- Tags: ctgov-sponsor
- HQ: Norwood, MA
- Type: biotech
- Website: https://www.corbuspharma.com

## Sources

- Official website: https://www.corbuspharma.com
- ClinicalTrials.gov: trials led by Corbus Pharmaceuticals: https://clinicaltrials.gov/search?lead=Corbus%20Pharmaceuticals%20Inc.

## Connected records

- drugs: [CRB-701](https://onco.cc/drugs/crb-701/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)
- trials: [A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors](https://onco.cc/trials/nct06265727/), [First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.](https://onco.cc/trials/nct06603844/)

---
JSON: https://onco.cc/api/v1/entities/corbus-pharmaceuticals.json